+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Non-Proliferative Diabetic Retinopathy (NPDR) Disease - Global Clinical Trials Review, H2 2020

  • PDF Icon

    Clinical Trials

  • 94 Pages
  • October 2020
  • Region: Global
  • GlobalData
  • ID: 5187139
Summary

The publisher's clinical trial report, “Non-Proliferative Diabetic Retinopathy (NPDR) Disease - Global Clinical Trials Review, H2, 2020“. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to Buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Report Guidance
  • Clinical Trials Report Coverage

Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase
  • In Progress Trials by Phase

Clinical Trials by Trial Status
Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials

Prominent Drugs
  • Clinical Trial Profile Snapshots

Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About the Publisher
  • Contact
  • Source

List of Tables
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Region, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Europe, Top Five Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, North America, Top Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Central and South America, Top Countries, 2020*
  • Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Phase 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*

List of Figures
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Region (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, North America, Top Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2020*
  • Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Phase (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
  • Methodology

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Novartis AG
  • AbbVie Inc
  • C. H. Boehringer Sohn AG & Co KG
  • F. Hoffmann-La Roche Ltd
  • Oxurion NV
  • Regeneron Pharmaceuticals Inc
  • Aerpio Pharmaceuticals Inc
  • Bausch Health Companies Inc
  • Tasly Holding Group Co Ltd
  • ZeaVision LLC